Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative
treatments for solid cancers, today announced that the safety data from the
patients in the safety lead-in cohort of its ongoing Phase 2 trial evaluating
Radspherin® for the treatment of peritoneal carcinomatosis from ovarian cancer
has been reviewed by the company and study investigators. No safety concerns
were identified, and based on this review, the company is pleased to confirm
that the randomised part of the trial is now initiated, with the first patient
successfully enrolled.

Radspherin® is a novel alpha-radiation therapy designed for targeted, direct
treatment of cancers that have spread to body cavities. The Phase 2 is a
randomised, open label, multicentre trial (NCT06504147) assessing the efficacy
and safety of Radspherin® in patients with peritoneal metastases from ovarian
cancer following complete surgical resection and pre-operative chemotherapy.

"The positive outcome of the safety review is consistent with the safety profile
observed in earlier studies," said Oystein Soug, CEO of Oncoinvent. "This allows
us to confidently move forward into the randomised part of the trial, to
continue exploring Radspherin®'s potential as a treatment for peritoneal
carcinomatosis."

About Oncoinvent
Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases post-surgery, harnessing the benefits of modern
radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. Currently two phase 1/2a trials and one
randomized phase 2 trial are ongoing in the US, UK and Europe. Preliminary
clinical efficacy data are highly encouraging, and no serious toxicity or safety
concerns have been reported to date. The Oncoinvent team consists of approx. 30
employees and runs a state-of-the-art manufacturing facility to produce drug
products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the
Euronext Growth Oslo.


Forward-Looking Statements
All statements other than statements of historical facts contained in this press
release are forward-looking statements and are not a representation that
Oncoinvent's plans, estimates, or expectations will be achieved. These
forward-looking statements represent Oncoinvent's expectations as of the date of
this press release, and Oncoinvent disclaims any obligation to update the
forward-looking statements. These forward-looking statements are subject to
known and unknown risks and uncertainties that may cause actual results to
differ materially, including with respect to whether the results of clinical or
other studies will support the use of our product offerings, the impact of
results of such studies, our expectations of the reliability, accuracy and
performance of our tests, or of the benefits of our tests and product offerings
to patients, providers and payers.

For further information, please contact:
Oystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com 

Tore Kvam, Chief Financial Officer 
Email: kvam@oncoinvent.com